HIV & Heart Health

People living with HIV on effective treatment are living longer than ever before — and that is genuinely good news. But longer life with HIV has revealed something the epidemic's early years couldn't show us: the heart pays a price that goes beyond the traditional risk factors of smoking, diet, and inactivity.

Research now consistently shows that people living with HIV have approximately 1.5 to 2 times higher risk of cardiovascular events — heart attacks, strokes, heart failure — compared to HIV-negative peers of the same age, even when other risk factors are controlled for.^[1] Understanding why is the first step to protecting yourself.

Even when HIV is fully suppressed by treatment, the immune system remains in a state of low-level chronic activation. This persistent inflammation — measurable through markers like IL-6 and hsCRP — damages blood vessel walls over time, accelerating atherosclerosis (the buildup of plaque in arteries).^[1] This is the primary driver of the excess cardiovascular risk in well-treated PLHIV, and it is not fully eliminated by antiretroviral therapy.

Some older HIV medications — particularly certain protease inhibitors and older NRTIs — are associated with changes in lipid profiles, including elevated triglycerides and LDL cholesterol. Modern regimens have significantly improved metabolic profiles, and switching to a newer regimen often improves lipids substantially. If your lipid levels are abnormal, talk to your HIV provider about whether your regimen might be contributing.

Smoking rates among PLHIV are 2–3 times higher than the general population.^[3] Rates of hypertension, diabetes, and metabolic syndrome are elevated. Depression — which is more prevalent among PLHIV — is itself a cardiovascular risk factor. These traditional risks don't just add to HIV-related inflammation risk; they interact with it, compounding the effect.

Most HIV providers are excellent at managing HIV. Cardiovascular medicine is a different specialty — and given the elevated risk profile for PLHIV, establishing care with a cardiologist for at least an annual assessment is something every person living with HIV should discuss with their HIV provider.

You don't need symptoms to see a cardiologist. A preventive cardiology visit is about baseline assessment, risk stratification, and establishing a relationship with a specialist who knows your heart before anything goes wrong.

Blood pressure is one of the most important numbers in cardiovascular health — and one of the most undertreated conditions in the HIV community. Hypertension often has no symptoms until it causes damage. Knowing your numbers and understanding what they mean is the foundation of heart health monitoring.

Blood pressure is written as two numbers: systolic / diastolic — for example, 120/80. The systolic (top) number is the pressure in your arteries when your heart beats. The diastolic (bottom) number is the pressure between beats. Both matter. The categories below follow the 2017 ACC/AHA hypertension guideline.^[6]

A lipid panel measures the fats in your blood. For PLHIV, this panel should be checked at baseline when starting treatment and at least annually thereafter — more often if levels are abnormal or you've changed your ART regimen.

LDL cholesterol ("bad") — the primary driver of arterial plaque. Lower is better. For PLHIV at elevated cardiovascular risk, many providers aim for LDL below 100 mg/dL, or below 70 mg/dL for high-risk patients.

HDL cholesterol ("good") — higher is protective. Below 40 mg/dL (men) or 50 mg/dL (women) is considered a risk factor. Exercise raises HDL.

Triglycerides — fats in the blood linked to metabolic syndrome. Below 150 mg/dL is normal. Some older HIV medications (particularly certain protease inhibitors) can significantly elevate triglycerides. Alcohol also raises triglycerides.

Non-HDL cholesterol — increasingly used as a more complete risk marker. Your total cholesterol minus your HDL.

Wearable fitness trackers and smartwatches have become genuinely useful health monitoring tools — not just step counters. For PLHIV paying attention to cardiovascular health, several metrics are worth tracking. Here's what matters and what to keep in perspective.

Alcohol use is more common among PLHIV than in the general population, and the cardiovascular implications are significant and often underappreciated. The relationship between alcohol and heart health is not simple — but for people already carrying elevated cardiovascular risk, the calculus matters.

Heavy alcohol use is a direct cardiotoxin. It raises blood pressure, elevates triglycerides, can cause alcoholic cardiomyopathy (weakening of the heart muscle) with long-term heavy use, and significantly increases the risk of atrial fibrillation. Even moderate alcohol use raises blood pressure in some people.

The "moderate alcohol is good for your heart" narrative that dominated public health messaging for decades has been substantially revised. More recent research suggests much of that protective association was due to methodological flaws — and that for people with existing cardiovascular risk factors, even moderate use may not be beneficial.

Alcohol affects liver function, and the liver metabolizes both alcohol and antiretroviral medications. Heavy alcohol use can reduce ART effectiveness by impairing adherence (missing doses when drinking heavily) and by competing for hepatic metabolism pathways. It also accelerates liver fibrosis in people co-infected with hepatitis B or C.

Some specific interactions worth knowing: alcohol combined with abacavir (Ziagen, in Epzicom, Triumeq) can increase abacavir blood levels. Alcohol with metronidazole (sometimes used for HIV-related infections) causes a severe reaction. Always ask your HIV provider or pharmacist about alcohol interactions with your specific regimen.

Cannabis use is more prevalent among PLHIV than in the general population — used for nausea, appetite stimulation, pain, anxiety, and sleep. Florida has a medical marijuana program, and CBD products are widely available. Here's an honest look at what the evidence shows for both cardiac implications and ART interactions.

The cardiovascular effects of cannabis are more complex than its reputation suggests. Acutely, cannabis — particularly smoked — causes a temporary increase in heart rate (sometimes significantly) and can trigger episodes of angina in people with existing coronary disease. There is growing evidence linking cannabis use, particularly smoked cannabis, to increased risk of heart attack and stroke, especially in younger users.^[8]

Smoked cannabis carries many of the same combustion byproducts as cigarettes and has similar effects on respiratory inflammation and endothelial function. Vaporized or edible cannabis avoids combustion products but still carries the acute cardiovascular effects of THC.

CBD alone — without significant THC — has a much lower cardiovascular risk profile and is not associated with the tachycardia or acute BP effects of THC-containing products.

This is the area of most direct clinical concern for PLHIV. Cannabis — both THC and CBD — is metabolized by the same liver enzyme system (CYP3A4) as many antiretroviral medications. This creates potential for drug interactions that can either increase or decrease ART blood levels.^[9]

Of particular concern: cannabinoids can affect levels of protease inhibitors, cobicistat-boosted regimens, and some NNRTIs. The interactions are not fully characterized — the research is still catching up with cannabis use rates among PLHIV. The most important thing you can do is be honest with your HIV provider about your cannabis use so they can flag potential interactions with your specific regimen.

The elevated cardiovascular risk in HIV has a biological component that medication and monitoring address — but lifestyle interventions are where you have the most direct personal agency. The evidence for these is robust and applies with particular force to PLHIV.

Studies modeling cardiovascular risk in PLHIV consistently show that smoking cessation has a larger impact on cardiovascular outcomes than almost any other single intervention — including statin therapy. PLHIV who smoke lose more life-years to smoking-related cardiovascular disease than to HIV itself. If you smoke, quitting is the highest-leverage health decision you can make. Florida has free smoking cessation resources — ask your HIV provider for a referral or call 1-800-QUIT-NOW.^[12]

Regular aerobic exercise reduces blood pressure, improves lipid profiles, raises HDL, lowers resting heart rate, reduces inflammation markers, and improves insulin sensitivity — all directly relevant to HIV-related cardiovascular risk. The American Heart Association recommends 150 minutes of moderate aerobic activity per week.^[10] For PLHIV starting from a sedentary baseline, even 30 minutes of walking 5 days a week produces measurable cardiovascular benefit.

Resistance training also has cardiovascular benefits and is particularly important for PLHIV experiencing sarcopenia (muscle loss) related to aging or past illness. Exercise is one of the most effective interventions for reducing chronic inflammation.

A Mediterranean-style diet — rich in vegetables, legumes, whole grains, olive oil, fish, and nuts, with limited red meat and processed foods — has the strongest evidence base for cardiovascular protection.^[11] For PLHIV with elevated triglycerides, reducing refined carbohydrates and sugar is particularly effective. Sodium reduction is the primary dietary intervention for blood pressure.

Finding a cardiologist who understands HIV — or at minimum is willing to learn — makes a significant difference in the quality of your cardiovascular care. Your HIV provider is your best starting point for a referral to a cardiologist who works with PLHIV or sees patients at an academic medical center with HIV expertise.